ROX指数预测Covid-19相关低氧性急性呼吸衰竭经鼻高流量氧疗结局的性能
该多中心回顾性队列研究纳入99例首次接受HFNO治疗的Covid-19急性呼吸衰竭患者,其中49例HFNO失败(46例插管、3例插管前死亡)。HFNO启动时(H0)ROX指数灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%);H12以4.88为界值时灵敏度29%(95%CI 14-48%)、特异度90%(95%CI 78-97%),Youden指数给出的8.73界值灵敏度87%(95%CI 70-96%)、特异度45%(95%CI 31-60%)。单因素分析H0 ROX指数与HFNO失败相关(p=0.0005),但多因素分析中SAPS II(p=0.0003)和肺部损伤影像学范围(p=0.0263)而非ROX指数可预测HFNO失败。作者认为ROX指数界值似乎具有人群特异性,判别能力临床价值低。
要点
- 99例Covid-19急性呼吸衰竭首次HFNO患者中49例失败(46例插管、3例插管前死亡)。
- H0 ROX指数以Youden指数为界值时灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%)。
- H12以4.88为界值时灵敏度仅29%(95%CI 14-48%)、特异度90%(95%CI 78-97%)。
- 多因素分析中SAPS II(p=0.0003)和肺部损伤影像学范围(p=0.0263)预测HFNO失败,ROX指数未进入。
- 作者认为ROX指数界值似乎具有人群特异性,判别HFNO失败与成功的临床能力低。
适用人群与场景
- 多中心回顾性队列中连续纳入的Covid-19急性呼吸衰竭患者,共筛查218例,其中99例首次接受HFNO治疗。
诊断标准与关键阈值
- ROX指数=SpO2/FiO2与呼吸频率的比值。
- H0以Youden指数确定界值,灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%)。
- H12以4.88为界值,灵敏度29%(95%CI 14-48%)、特异度90%(95%CI 78-97%)。
- H12 Youden指数界值为8.73,灵敏度87%(95%CI 70-96%)、特异度45%(95%CI 31-60%)。
研究设计与关键结果
- 研究类型为多中心回顾性队列研究,筛查218例Covid-19急性呼吸衰竭患者,99例首次接受HFNO,其中49例HFNO失败(46例插管、3例插管前死亡)。
- H0 ROX指数灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%);H12以4.88为界值灵敏度29%(95%CI 14-48%)、特异度90%(95%CI 78-97%);H12 Youden指数界值8.73时灵敏度87%(95%CI 70-96%)、特异度45%(95%CI 31-60%)。
- 单因素分析H0 ROX指数与HFNO失败相关(p=0.0005)。
- 多因素分析显示SAPS II(p=0.0003)和肺部损伤影像学范围(p=0.0263)而非ROX指数可预测HFNO失败。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 作者结论:ROX指数界值似乎具有人群特异性,ROX指数判别HFNO失败与成功的准确性技术上可接受但临床能力低;SAPS II和入ICU时肺部损伤似乎比ROX指数更有用于预测插管风险。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ROX指数界值似乎具有人群特异性,在Covid-19急性呼吸衰竭患者中判别HFNO失败与成功的临床能力低。
- 作者认为SAPS II和入ICU时肺部损伤影像学范围似乎比ROX指数更有用于预测插管风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Given the pathophysiology of hypoxemia in patients with Covid-19 acute respiratory failure (ARF), it seemed necessary to evaluate whether ROX index (ratio SpO2/FiO2 to respiratory rate) could accurately predict intubation or death in these patients initially treated by high-flow nasal oxygenation (HFNO). We aimed, therefore, to assess the accuracy of ROX index to discriminate between HFNO failure (sensitivity) and HFNO success (specificity).
METHODS: We designed a multicentre retrospective cohort study including consecutive patients with Covid-19 ARF. In addition to its accuracy, we assessed the usefulness of ROX index to predict HFNO failure (intubation or death) via logistic regression.
RESULTS: Among 218 ARF patients screened, 99 were first treated with HFNO, including 49 HFNO failures (46 intubations, 3 deaths before intubation). At HFNO initiation (H0), ROX index sensitivity was 63% (95%CI 48-77%) and specificity 76% (95%CI 62-87%) using Youden's index. With 4.88 as ROX index cut-off at H12, sensitivity was 29% (95%CI 14-48%) and specificity 90% (95%CI 78-97%). Youden's index yielded 8.73 as ROX index cut-off at H12, with 87% sensitivity (95%CI 70-96%) and 45% specificity (95%CI 31-60%). ROX index at H0 was associated with HFNO failure (p = 0.0005) in univariate analysis. Multivariate analysis showed that SAPS II (p = 0.0003) and radiographic extension of pulmonary injuries (p = 0.0263), rather than ROX index, were predictive of HFNO failure.
CONCLUSIONS: ROX index cut-off values seem population-specific and the ROX index appears to have a technically acceptable but clinically low capability to discriminate between HFNO failures and successes in Covid-19 ARF patients. In addition, SAPS II and pulmonary injuries at ICU admission appear more useful than ROX index to predict the risk of intubation.
参考来源
- Girault C, Bubenheim M, Boyer D, et al. ROX index performance to predict high-flow nasal oxygen outcome in Covid-19 related hypoxemic acute respiratory failure. Ann Intensive Care. 2024. PMID: 38236356. doi:10.1186/s13613-023-01226-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。